Hikma Pharmaceuticals (BATS-CHIXE:HIKL) - Aandelenkoers, Nieuws & Analyse

HIKL Overzicht aandelen

Hikma Pharmaceuticals PLC ontwikkelt, produceert, verkoopt en verhandelt een reeks generieke farmaceutische producten, merkproducten en farmaceutische producten onder licentie. Meer informatie

HIKL fundamentele analyse
Sneeuwvlok Score
Waardering	6/6
Toekomstige groei	1/6
Prestaties in het verleden	3/6
Financiële gezondheid	4/6
Dividenden	5/6

Beloningen

Verhandeld tegen 52% onder onze schatting van de reële waarde

De winst zal naar verwachting met 11.18% per jaar groeien

De winst groeide het afgelopen jaar met 95.2%

Betaalt een betrouwbaar dividend van 3.48%

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Analisten zijn het erover eens dat de aandelenkoers met 29% zal stijgen

Risicoanalyse

Heeft een hoog schuldenniveau

Grote eenmalige posten die de financiële resultaten beïnvloeden

Hikma Pharmaceuticals PLC Concurrenten

GSK

LSE:GSK

UK£55.2b

Animalcare Group

AIM:ANCR

UK£143.1m

AstraZeneca

LSE:AZN

UK£159.6b

ECO Animal Health Group

AIM:EAH

UK£46.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Hikma Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	UK£17.96
52 Week Hoogtepunt	UK£21.61
52 Week Laag	UK£17.11
Bèta	0.44
11 maand verandering	-8.41%
3 maanden verandering	-13.11%
1 Jaar Verandering	3.91%
33 jaar verandering	-21.43%
5 jaar verandering	-4.60%
Verandering sinds IPO	181.28%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	HIKL	GB Pharmaceuticals	GB Markt
7D	0.1%	3.5%	-1.0%
1Y	3.9%	0.4%	6.9%

Rendement versus industrie: HIKL overtrof de UK Pharmaceuticals industrie, die het afgelopen jaar een rendement 0.4 % opleverde.

Rendement versus markt: HIKL presteerde slechter dan UK Market, dat het afgelopen jaar een rendement van 6.9 % opleverde.

Prijsvolatiliteit

Is HIKL's price volatile compared to industry and market?
HIKL volatility
HIKL Average Weekly Movement	2.6%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.1%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: HIKL heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van HIKL is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1978	9,100	Riad Mishlawi	www.hikma.com

Hikma Pharmaceuticals PLC ontwikkelt, produceert, verkoopt en verhandelt een reeks generieke en merkgeneesmiddelen en farmaceutische producten onder licentie. Het bedrijf is actief in drie segmenten: Injectables, Generics en Branded. Het segment Injectables levert generische injecteerbare producten, voornamelijk voor gebruik in ziekenhuizen.

Hikma Pharmaceuticals PLC Samenvatting

Hoe verhouden de winst en inkomsten van Hikma Pharmaceuticals zich tot de beurswaarde?
HIKL fundamentele statistieken
Marktkapitalisatie	UK£3.98b
Inkomsten(TTM)	UK£225.16m
Inkomsten(TTM)	UK£2.38b

17.7x

Koers/Winstverhouding

1.7x

P/S-verhouding

Is HIKL overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
HIKL resultatenrekening (TTM)
Inkomsten	US$3.02b
Kosten van inkomsten	US$1.57b
Brutowinst	US$1.45b
Overige uitgaven	US$1.16b
Inkomsten	US$285.00m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	1.29
Brutomarge	47.99%
Nettowinstmarge	9.45%
Schuld/Eigen Vermogen Verhouding	53.2%

Hoe presteerde HIKL op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

3.5%

Huidig dividendrendement

61%

Uitbetalingsratio

HIKL Overzicht aandelen

Beloningen

Risicoanalyse

Hikma Pharmaceuticals PLC Concurrenten

LSE:GSK

UK£55.2b

AIM:ANCR

UK£143.1m

LSE:AZN

UK£159.6b

AIM:EAH

UK£46.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Hikma Pharmaceuticals plc Announces the Shelf-Life Extension of KLOXXADO Nasal Spray 8mg from 24 to 36 Months

Hikma Pharmaceuticals PLC Revises Group Earnings Guidance for the Full Year of 2024

Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024

Hikma Pharmaceuticals PLC Announces Executive Changes

Upcoming dividend of US$0.47 per share

Now 21% undervalued

Recent updates

Hikma Pharmaceuticals plc Announces the Shelf-Life Extension of KLOXXADO Nasal Spray 8mg from 24 to 36 Months

Hikma Pharmaceuticals PLC Revises Group Earnings Guidance for the Full Year of 2024

Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024

Hikma Pharmaceuticals PLC Announces Executive Changes

Upcoming dividend of US$0.47 per share

Now 21% undervalued

Final dividend of US$0.47 announced

Full year 2023 earnings released: EPS: US$0.86 (vs US$0.84 in FY 2022)

Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 25, 2024

Hikma Announces US Launch of COMBOGESIC IV

Now 22% undervalued after recent price drop

Hikma Pharmaceuticals PLC Announces Company Secretary Change

Hikma Pharmaceuticals PLC to Report First Half, 2024 Results on Aug 08, 2024

Hikma Pharmaceuticals PLC Provides Earnings Guidance for the Year 2023

Hikma Pharmaceuticals PLC(LSE:HIK) dropped from FTSE 250 Index

Now 21% undervalued

New minor risk - Insider selling

Insider recently sold UK£543k worth of stock

Hikma Pharmaceuticals PLC Appoints Bill Larkins as President of Its Injectables Business, Effective 1 September 2023

First half 2023 earnings released: EPS: US$0.59 (vs US$0.76 in 1H 2022)

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Hikma Exceeds 150 Injectable Medicines in the US with Launch of Dobutamine Injection, USP

Now 21% undervalued

Upcoming dividend of US$0.37 per share at 2.7% yield

Full year 2022 earnings released: EPS: US$0.84 (vs US$1.82 in FY 2021)

Hikma Launches Authorized Generic of Xyrem® (Sodium Oxybate) in the US

Hikma Pharmaceuticals PLC to Report Fiscal Year 2022 Results on Feb 23, 2023

Hikma Pharmaceuticals PLC Appoints Deneen Vojta as Director

Hikma Pharmaceuticals PLC Announces Board Appointments

Investor sentiment improved over the past week

Hikma Pharmaceuticals PLC(LSE:HIK) dropped from FTSE 100 Index

Hikma Pharmaceuticals PLC and Glenmark Specialty S.A., Launches RYALTRIS in US

Upcoming dividend of US$0.19 per share

First half 2022 earnings released

Hikma Pharmaceuticals plc Recommends Interim Dividend, Payable on 19 September 2022

Insufficient new directors

Insufficient new directors

Hikma Pharmaceuticals plc Announces Company Secretary Change

Hikma Pharmaceuticals PLC Announces Chief Executive Officer Changes

Hikma Pharmaceuticals PLC Approves Final Dividend for the Year 2021

Hikma Pharmaceuticals PLC (LSE:HIK) completed the acquisition of Custopharm Inc. from Water Street Healthcare Partners, LLC.

Upcoming dividend of US$0.36 per share

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Hikma Pharmaceuticals PLC (LSE:HIK) announces an Equity Buyback for £300 million worth of its shares.

Hikma Pharmaceuticals PLC Provides Revenue Guidance for 2022

Hikma Pharmaceuticals PLC (LSE:HIK) completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).

Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Canadian assets of Teligent Inc. from Teligent, Inc. (OTCPK:TLGT.Q) for $45.7 million.

Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Custopharm Inc. from Water Street Healthcare Partners, LLC for approximately $430 million.

Upcoming dividend of US$0.18 per share

First half 2021 earnings released: EPS US$1.07 (vs US$0.88 in 1H 2020)

Hikma Pharmaceuticals PLC Announces US FDA Approval of KLOXXADO

New 90-day low: UK£22.38

Full year 2020 earnings released: EPS US$1.83 (vs US$2.01 in FY 2019)

Revenue beats expectations

Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 23, 2021

Eyevance Pharmaceuticals Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma

Hikma Pharmaceuticals PLC to Report Fiscal Year 2020 Results on Feb 25, 2021

Hikma Pharmaceuticals PLC (LSE:HIK) entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E (CASE:BIOC) from Glaxo Group Limited.